Central nervous system aspergillosis in immunocompetent patients

Abstract

The aim of this study was to investigate the clinical characteristics of central nervous system (CNS) aspergillosis in immunocompetent patients. This study enrolled six immunocompetent patients diagnosed with CNS aspergillosis. Additionally, we reviewed the clinical profiles for 28 cases reported in the literature. The age, gender, etiology of Aspergillus infection, clinical manifestations, location of the lesion, treatment, and prognosis were analyzed. There were 19 men (average age, 54.6 ± 14.3 years) and 15 women (average age, 47.0 ± 19.4 years). The clinical manifestations included headache (55.9%; n = 19), visual impairment (32.4%; n = 11), diplopia (32.4%; n = 11), hemiplegia (20.6%; n = 7), fever (17.6%; n = 6), and epilepsy (8.8%; n = 3). According to the radiological features, CNS aspergillosis lesions were divided into two subtypes: parenchymal lesions in the cerebral lobes (n = 11), and meningeal lesions in the meninges (n = 23). The patients with meningeal lesions are easy to be complicated with more serious cerebrovascular diseases, such as subarachnoid hemorrhage and massive infarction. Most of the lesions in brain parenchyma were abscess formation, and magnetic resonance imaging showed ring enhancement. The clinical diagnosis of Aspergillus infection was mainly based on brain biopsy (n = 14), autopsy (n = 8), pathological examination of adjacent brain tissues (n = 7), cerebrospinal fluid (CSF) or tissue culture (n = 3), and second-generation sequencing analysis of the CSF (n = 3). Clinical improvement was achieved in 23 cases, and 11 patients succumbed to the disease. Voriconazole treatment was effective in 24 (70.6%) cases. Immunocompetent subjects are also at risk for Aspergillus infections. Concomitant cerebrovascular diseases are common in patients with CNS aspergillosis, especially in patients with meningeal aspergillosis. Parenchymal aspergillosis lesions are usually localized and manifest as brain abscesses with annular enhancement on magnetic resonance imaging. Biopsy, CSF culture, and next-generation sequencing are mainstream diagnostic modalities. Voriconazole is an effective treatment for Aspergillus infection, and early diagnosis and treatment should be highlighted.

Rapid Genomic Diagnosis of Fungal Infections in the Age of Next-Generation Sequencing

“…Lastly, publications were searched using specific fungal names and after manual examination five extra articles were added. Therefore, in total 52 articles were included in this review [ 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 ].…”

“…It was a case of allergic bronchopulmonary mycosis where A. fumigatus and Schizophyllum commune sequences were detected in the homogenised sputum and mucoid plugs of the patient [ 26 ]. Since then, up to the time of writing, a total of 319 cases of fungal infections diagnosed by NGS were described in the literature, with some in case reports and others in case series or cohorts [ 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 ]. In 40 out of the 319 cases (12.5%), more than 1 fungus was detected by NGS [ 26 , ...…”

Cerebral aspergillose

“…På verdensbasis har det vaert økt forekomst av opportunistiske infeksjoner som soppinfeksjoner de siste tiårene. Dette antas blant annet å vaere på grunn av økt forekomst av immunsupprimerte pasienter, saerlig etter fremskritt innen transplantasjon og flere behandlingsmuligheter for inflammatoriske sykdommer (1). Medikamentell immunsuppresjon, saerlig kortikosteroidbehandling, øker risikoen for aspergillose i sentralnervesystemet (2).…”

“…Medikamentell immunsuppresjon, saerlig kortikosteroidbehandling, øker risikoen for aspergillose i sentralnervesystemet (2). Denne infeksjonen har en mortalitet på 85-100 % hos immunsupprimerte pasienter (1). Infeksjonene oppstår oftest gjennom hematogen spredning fra de primaere infeksjonsstedene, vanligvis lunger, eller via direkte spredning fra bihuler.…”

Marine Bioactive Compounds against Aspergillus fumigatus: Challenges and Future Prospects

“…Cases of varying kinds of aspergillosis have been reported among non-immunocompromised patients for years now, such as craniocerebral aspergillosis of sino-nasal origin [ 49 , 50 ], chronic invasive sinus aspergillosis [ 51 ], orbital aspergillosis [ 52 , 53 , 54 ], fatal invasive aspergillosis [ 55 ], intracranial aspergillosis [ 56 ], central nervous system aspergillosis [ 57 ], pulmonary aspergillosis [ 58 , 59 ], and adrenal and hepatic aspergillosis [ 60 ].…”